{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:55:07Z","timestamp":1765875307587,"version":"3.48.0"},"reference-count":24,"publisher":"Korean Ophthalmological Society","issue":"6","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["18-2023-0014"],"award-info":[{"award-number":["18-2023-0014"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ekjo.org"],"crossmark-restriction":true},"short-container-title":["Korean J Ophthalmol"],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:p>Purpose: To investigate the anatomical and functional outcomes in cases of re-switching to previous anti?vascular endothelial growth factor (anti-VEGF) agents due to intraocular inflammation (IOI) following a switch to brolucizumab in neovascular age-related macular degeneration.Methods: This study included patients with neovascular age-related macular degeneration who switched to brolucizumab and discontinued brolucizumab treatment due to IOI, with a follow-up duration of at least 6 months before and after brolucizumab treatment period. Changes in best-corrected visual acuity, central macular thickness, central choroidal thickness, and retinal fluid on optical coherence tomography were evaluated.Results: A total of 16 eyes from 16 patients were reviewed. Two patients (12.5%) achieved complete fluid resolution before brolucizumab treatment, which increased to 15 (93.8%) during brolucizumab therapy. However, after switching back to other anti-VEGF agents, the proportion of patients with dry macula decreased to 37.5%. There were no statistically significant changes in best-corrected visual acuity, central macular thickness, central choroidal thickness throughout the study period.Conclusions: In cases where brolucizumab treatment was discontinued due to IOI and switched back to other anti-VEGF agents, the anatomical response was insufficient, indicating the need for alternative treatment options.<\/jats:p>","DOI":"10.3341\/kjo.2025.0008","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:35:37Z","timestamp":1758000937000},"page":"493-500","update-policy":"https:\/\/doi.org\/10.3341\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Re-Switching Anti&amp;amp;#x02013;Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration"],"prefix":"10.3341","volume":"39","author":[{"given":"Young Kun","family":"Suh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1893","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200512000-00016"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52747-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2023.0009"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2023.0145"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2007.21.4.213"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.09.020"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2023.0133"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122666"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2021.05.003"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.06.009"},{"key":"ref13","first-page":"89","volume-title":"HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","author":"Dugel","year":"2021"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73782-1"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000529410"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.21561\/jor.2022.7.2.113"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420930863"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.TJO-D-23-00112"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/aos.16699"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.ijo_2688_22"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-022-00908-1"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38173-y"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.21561\/jor.2021.6.2.145"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.21561\/jor.2024.9.2.156"}],"container-title":["Korean Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ekjo.org\/upload\/pdf\/kjo-2025-0008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2025.0008","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ekjo.org\/upload\/pdf\/kjo-2025-0008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:50:24Z","timestamp":1765875024000},"score":1,"resource":{"primary":{"URL":"http:\/\/ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2025.0008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.3341\/kjo.2025.0008","relation":{},"ISSN":["1011-8942","2092-9382"],"issn-type":[{"type":"print","value":"1011-8942"},{"type":"electronic","value":"2092-9382"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2025-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-16","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}